Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.

Krüger K, Krauth C, Rossol S, Mauss S, Boeker KHW, Müller T, Klinker H, Pathil A, Heyne R, Stahmeyer JT; Collaborators DHC-R.

Eur J Gastroenterol Hepatol. 2019 Feb;31(2):230-240. doi: 10.1097/MEG.0000000000001283.

PMID:
30325794
2.

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C.

PLoS One. 2017 Jan 3;12(1):e0169401. doi: 10.1371/journal.pone.0169401. eCollection 2017.

3.

Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis.

Bert F, Stahmeyer JT, Rossol S.

J Clin Med Res. 2016 Sep;8(9):650-5. doi: 10.14740/jocmr2625w. Epub 2016 Jul 30.

4.

[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].

Stahmeyer JT, Rossol S, Bert F, Liersch S, Krauth C.

Z Gastroenterol. 2016 Aug;54(8):760-9. doi: 10.1055/s-0042-105655. Epub 2016 Aug 16. German.

PMID:
27529526
5.

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.

Stahmeyer JT, Rossol S, Bert F, Böker KH, Bruch HR, Eisenbach C, Link R, John C, Mauss S, Heyne R, Schott E, Pfeiffer-Vornkahl H, Hüppe D, Krauth C.

PLoS One. 2016 Jul 28;11(7):e0159976. doi: 10.1371/journal.pone.0159976. eCollection 2016.

6.

High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit.

Bert F, Rindermann A, Abdelfattah MA, Stahmeyer JT, Rossol S.

Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1246-52. doi: 10.1097/MEG.0000000000000702.

PMID:
27439034
7.

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.

Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S.

J Viral Hepat. 2016 Feb;23(2):105-15. doi: 10.1111/jvh.12471. Epub 2015 Sep 28.

PMID:
26411532
8.

Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.

Stahmeyer JT, Rossol S, Krauth C.

J Comp Eff Res. 2015 May;4(3):267-277. doi: 10.2217/cer.15.13. Epub 2015 May 11.

PMID:
25960028
9.

[Rare cause of recurrent subileus].

Bert F, Rossol S.

Dtsch Med Wochenschr. 2015 Apr;140(9):670-2. doi: 10.1055/s-0041-101519. Epub 2015 Apr 29. German.

PMID:
25924047
10.

Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.

Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, Hüppe D, Teuber G, Wiebner B, Wedemeyer H, Krauth C.

Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1278-85. doi: 10.1097/MEG.0000000000000181.

PMID:
25144493
11.

[Costs of a guideline-based treatment of patients with chronic hepatitis C in Germany].

Stahmeyer JT, Rossol S, Bert F, Abdelfattah M, Krauth C.

Z Gastroenterol. 2014 Sep;52(9):1041-9. doi: 10.1055/s-0034-1366289. Epub 2014 Jul 30. German.

PMID:
25075995
12.

A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study.

Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Rossol S, Pfeiffer B, Schellong SM.

J Thromb Haemost. 2010 Jun;8(6):1209-15. doi: 10.1111/j.1538-7836.2010.03848.x. Epub 2010 Mar 9.

13.

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.

Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB.

Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006.

PMID:
19485429
14.

Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker.

Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roeßler M, Palme S, Karl J, Bodenmüller H, Rüschoff J, Rossol S, Rohr G, Rösch W, Friess H, Eickhoff A, Jauch KW, Langen H, Zolg W, Tacke M.

Proteomics Clin Appl. 2008 Jan;2(1):11-22. doi: 10.1002/prca.200780046. Epub 2007 Dec 11. No abstract available.

PMID:
21136775
15.

[Constipation in patients with diabetes mellitus].

Rossol S.

MMW Fortschr Med. 2007 Nov 1;149(44):39-42. Review. German.

PMID:
18078169
16.

[Chronic hepatitis C virus infection].

Rossol S, Bartel J.

MMW Fortschr Med. 2006 Oct 26;148(43):36-7. German.

PMID:
17619422
17.

[Chronic HCV infections. A model disease for therapy, economics and social-medical aspects].

Rossol S.

Gesundheitswesen. 2007 Mar;69(3):146-50. Review. German.

PMID:
17440844
18.

Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis.

Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M.

Mol Cell Proteomics. 2006 Nov;5(11):2092-101. Epub 2006 Aug 6.

19.

[Health economics in hepatology: who should pay? Is expensive treatment in hepatology cost effective?].

Rossol S.

Dtsch Med Wochenschr. 2005 Dec 16;130 Suppl 5:S231-3. German. No abstract available.

PMID:
16435721
20.

[Health economics of chronic infectious diseases: the example of hepatitis C].

Wasem J, Sroczynski G, Aidelsburger P, Buchberger B, Hessel F, Conrads-Frank A, Peters-Blöchinger A, Kurth BM, Wong JB, Rossol S, Siebert U.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):57-63. German.

PMID:
16341606
21.

Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.

Roessler M, Rollinger W, Palme S, Hagmann ML, Berndt P, Engel AM, Schneidinger B, Pfeffer M, Andres H, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M.

Clin Cancer Res. 2005 Sep 15;11(18):6550-7.

22.

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany.

Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, Kurth BM, Bullinger M, von der Schulenburg JM, Wong JB, Rossol S.

Eur J Health Econ. 2005 Jun;6(2):112-23.

PMID:
15902546
23.

Polymorphisms in the IL-12B gene and outcome of HCV infection.

Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG, Cramp ME.

J Interferon Cytokine Res. 2005 May;25(5):271-6.

PMID:
15871664
24.

Antiviral treatment initiation costs in chronic hepatitis C.

Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB.

Gut. 2005 Jan;54(1):172-3. No abstract available.

26.

Hepatitis B core antigen is a potent inductor of interleukin-18 in peripheral blood mononuclear cells of healthy controls and patients with hepatitis B infection.

Manigold T, Böcker U, Chen J, Gundt J, Traber P, Singer MV, Rossol S.

J Med Virol. 2003 Sep;71(1):31-40.

PMID:
12858406
27.

Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis.

Manigold T, Böcker U, Hanck C, Gundt J, Traber P, Antoni C, Rossol S.

Eur J Gastroenterol Hepatol. 2003 Mar;15(3):275-82.

PMID:
12610323
28.

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group.

Gut. 2003 Mar;52(3):425-32.

29.

Butyrate modulates intestinal epithelial cell-mediated neutrophil migration.

Böcker U, Nebe T, Herweck F, Holt L, Panja A, Jobin C, Rossol S, B Sartor R, Singer MV.

Clin Exp Immunol. 2003 Jan;131(1):53-60.

30.

Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression.

Böcker U, Yezerskyy O, Feick P, Manigold T, Panja A, Kalina U, Herweck F, Rossol S, Singer MV.

Int J Colorectal Dis. 2003 Jan;18(1):25-32. Epub 2002 Jun 14.

PMID:
12458377
31.

Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region.

Kalina U, Koyama N, Hosoda T, Nuernberger H, Sato K, Hoelzer D, Herweck F, Manigold T, Singer MV, Rossol S, Böcker U.

Eur J Immunol. 2002 Sep;32(9):2635-43.

32.
33.

Regulation of Staphylococcus aureus-mediated activation of interleukin-18 in peripheral blood mononuclear cells.

Böcker U, Manigold T, Watson JM, Singer MV, Rossol S.

Eur Cytokine Netw. 2001 Oct-Dec;12(4):631-8.

34.

Flux of amino acids and energy substrates across the leg in weight-stable HIV-infected patients with acute opportunistic infections: indication of a slow protein wasting process.

Breitkreutz R, Wagner J, Tokus M, Benner A, Rossol S, Pittack N, Stein J, Dröge W, Holm E.

J Mol Med (Berl). 2001 Nov;79(11):671-8.

PMID:
11715071
35.

Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis.

Hanck C, Manigold T, Böcker U, Kurimoto M, Kölbel CB, Singer MV, Rossol S.

Gut. 2001 Jul;49(1):106-11.

36.

Source of endothelin-1 in subarachnoid hemorrhage.

Bertsch T, Kuehl S, Muehlhauser F, Walter S, Hodapp B, Rossol S, Schmeck J, Ragoschke A, Schütt S, Fritzinger M, Horn P, Vajkoczy P, Wellner MW, Fassbender K.

Clin Chem Lab Med. 2001 Apr;39(4):341-5.

PMID:
11388659
37.

Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries.

Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schütt S, Fritzinger M, Horn P, Vajkoczy P, Kreisel S, Brunner J, Schmiedek P, Hennerici M.

J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):534-7.

38.

Lipopolysaccharide/endotoxin induces IL-18 via CD14 in human peripheral blood mononuclear cells in vitro.

Manigold T, Böcker U, Traber P, Dong-Si T, Kurimoto M, Hanck C, Singer MV, Rossol S.

Cytokine. 2000 Dec;12(12):1788-92.

PMID:
11097749
39.

CD14+ peripheral blood mononuclear cells from chronic myeloid leukemia and normal donors are inhibitory to short- and long-term cultured colony-forming cells.

Heissig B, Pasternak G, Hörner S, Schwerdtfeger R, Rossol S, Hehlmann R.

Leuk Res. 2000 Mar;24(3):217-31.

PMID:
10739004
40.
41.

Immunopathogenesis of hepatitis B virus recurrence after liver transplantation.

Marinos G, Rossol S, Carucci P, Wong PY, Donaldson P, Hussain MJ, Vergani D, Portmann BC, Williams R, Naoumov NV.

Transplantation. 2000 Feb 27;69(4):559-68.

PMID:
10708112
42.

Gene expression of TNF-receptors in peripheral blood mononuclear cells of patients with alcoholic cirrhosis.

Hanck C, Glatzel M, Singer MV, Rossol S.

J Hepatol. 2000 Jan;32(1):51-7.

PMID:
10673067
43.

[Identification of CD81 protein as HCV receptor--relevance for pathogenesis and cell tropism?].

Rossol S.

Z Gastroenterol. 1999 Dec;37(12):1209-11. German. No abstract available.

PMID:
10666846
44.

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV.

Gastroenterology. 2000 Feb;118(2):346-55.

PMID:
10648463
45.

Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes.

Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schütt S, Fritzinger M, Horn P, Vajkoczy P, Wendel-Wellner M, Ragoschke A, Kuehl S, Brunner J, Schürer L, Schmiedeck P, Hennerici M.

Stroke. 2000 Dec;31(12):2971-5.

PMID:
11108758
46.

Immunological changes of mild acute pancreatitis in late-stage alcoholic chronic pancreatitis.

Hanck C, Rossol S, Singer MV.

Dig Dis Sci. 1999 Sep;44(9):1768-73.

PMID:
10505712
47.

Interferon-gamma-inducing factor (IL-18) and interferon-gamma in inflammatory CNS diseases.

Fassbender K, Mielke O, Bertsch T, Muehlhauser F, Hennerici M, Kurimoto M, Rossol S.

Neurology. 1999 Sep 22;53(5):1104-6.

PMID:
10496274
48.

Different IL-12p40 responses in hepatitis C virus-induced and alcohol-induced cirrhosis.

Hanck C, Singer MV, Rossol S.

Scand J Gastroenterol. 1999 Feb;34(2):221-2. No abstract available.

PMID:
10192207
49.

Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia.

Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov NV.

Gut. 1999 Mar;44(3):424-9.

50.

Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis.

Hanck C, Rossol S, Böcker U, Tokus M, Singer MV.

Alcohol Alcohol. 1998 Nov-Dec;33(6):606-8.

PMID:
9872348

Supplemental Content

Loading ...
Support Center